Notice: This company has been marked as potentially delisted and may not be actively trading. AzurRx BioPharma (AZRX) News Today Add Compare Share Share Headlines Stock AnalysisCompetitorsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Entero Therapeutics Inc (ENTO)July 31, 2024 | investing.comYS YS Biopharma Co., Ltd.April 11, 2024 | seekingalpha.comHanAll Biopharma Opens Applications for the 2023 Pharmaceutical Industry Fellowship ProgramApril 19, 2023 | finance.yahoo.comFirst Wave BioPharma Shares Jump 21% on FDA Review of Adrulipase IND FilingJanuary 15, 2023 | marketwatch.comFWBI First Wave BioPharma, Inc.September 16, 2022 | seekingalpha.comFirst Wave BioPharma Inc (FWBI)April 30, 2022 | investing.comFirst Wave BioPharma IncOctober 1, 2021 | reuters.comAzurRx BioPharma Changes Name to First Wave BioPharmaSeptember 21, 2021 | marketwatch.comAzurRx BioPharma to Change Corporate Name to First Wave BioPharma TodaySeptember 21, 2021 | finance.yahoo.comAzurRx BioPharma To Acquire First Wave Bio In Transformative $229 Million Deal; Significantly Expands GI and IBD Treatment Pipeline (NASDAQ: AZRX)September 14, 2021 | benzinga.comWhy AzurRx BioPharma's Stock Is Trading Higher TodaySeptember 14, 2021 | msn.comAzurRx (AZRX) Announces First Wave Bio Acquisition for $229MSeptember 14, 2021 | finance.yahoo.comAzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave ...September 14, 2021 | apnews.comAzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharmaSeptember 14, 2021 | finance.yahoo.comAzurRx BioPharma To Acquire First Wave Bio For $229MSeptember 13, 2021 | finance.yahoo.comAzurRx Announces Acquisition Of First Wave Bio, And Creation Of First Wave BioPharmaSeptember 13, 2021 | nasdaq.comAzurRx BioPharma, Inc.: AzurRx BioPharma Announces Reverse Stock SplitSeptember 13, 2021 | finanznachrichten.deAzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease IndicationsSeptember 13, 2021 | finance.yahoo.comAzurRx BioPharma Announces Reverse Stock SplitSeptember 10, 2021 | finance.yahoo.comAzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial ...September 10, 2021 | apnews.comAzurRx Activates New Clinical Trial Sites In India For Gastrointestinal Infections COVID-19 StudySeptember 10, 2021 | nasdaq.comAzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal InfectionsSeptember 10, 2021 | finance.yahoo.comDMC Recommends AzurRx Continues Gastrointestinal Infections COVID-19 StudySeptember 9, 2021 | markets.businessinsider.comAzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal InfectionsSeptember 9, 2021 | finance.yahoo.comAzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated ColitisSeptember 8, 2021 | finance.yahoo.comAzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment ConferenceSeptember 7, 2021 | ca.finance.yahoo.comAzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment ConferenceSeptember 7, 2021 | finance.yahoo.comAZURRX BIOPHARMA INC COM USD0.0001(AZRX)September 5, 2021 | fool.comAzurRx BioPharma Shares Rally on MS1819 Study Results >AZRXAugust 18, 2021 | marketwatch.comWhy AzurRx Stock Is Trading Higher After MS1819 Combo Therapy Data?August 18, 2021 | finance.yahoo.comAzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial ...August 18, 2021 | apnews.comAzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)August 18, 2021 | finance.yahoo.comAzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819August 17, 2021 | finance.yahoo.comAzurRx BioPharma Completes Initial Cohort Enrollment into Part 1 of its RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal InfectionsAugust 12, 2021 | finance.yahoo.comAzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal InfectionsAugust 10, 2021 | finance.yahoo.comAzurRx BioPharma Announces Closing of $5.75 Million Bought Deal Offering and Exercise in Full ...July 28, 2021 | apnews.comAzurRx BioPharma shares are trading lower after the company announced it increased its previously announced bought deal offering to $5 million.July 24, 2021 | benzinga.comAzurRx BioPharma, Inc. Common Stock (AZRX)July 23, 2021 | nasdaq.comAzurRx BioPharma Increases Previously Announced Bought Deal to $5.0 MillionJuly 22, 2021 | finance.yahoo.comAzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common StockJuly 22, 2021 | finance.yahoo.com Get AzurRx BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter. Email Address AZRX Media Mentions By Week AZRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AZRX News Sentiment▼0.000.63▲Average Medical News Sentiment AZRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AZRX Articles This Week▼00▲AZRX Articles Average Week Get AzurRx BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies COCP News MIRA News BOLT News OKUR News MEIP News TRAW News AFMD News BFRG News CARM News BTAI News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AZRX) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowPotential $20-trillion opportunity? Put $500 into THIS AI Coin for 2025… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AzurRx BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AzurRx BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
